{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:53:04Z","timestamp":1779889984563,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04617-1","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T23:48:43Z","timestamp":1675986523000},"page":"6399-6409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-5358","authenticated-orcid":false,"given":"Neha","family":"Pathak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroof Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Prakash","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"4617_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1054\/bjoc.2001.2162","volume":"85","author":"M Ando","year":"2001","unstructured":"Ando M, Ando Y, Hasegawa Y et al (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85:1634\u20131639. https:\/\/doi.org\/10.1054\/bjoc.2001.2162","journal-title":"Br J Cancer"},{"key":"4617_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.2007.13.1912","volume":"26","author":"CP Belani","year":"2008","unstructured":"Belani CP, Ramalingam S, Perry MC et al (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non\u2013small-cell lung cancer. JCO 26:468\u2013473. https:\/\/doi.org\/10.1200\/JCO.2007.13.1912","journal-title":"JCO"},{"key":"4617_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","volume":"89","author":"SP Blagden","year":"2003","unstructured":"Blagden SP, Charman SC, Sharples LD et al (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89:1022\u20131027. https:\/\/doi.org\/10.1038\/sj.bjc.6601231","journal-title":"Br J Cancer"},{"key":"4617_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jtho.2018.02.013","volume":"13","author":"P Bonomi","year":"2018","unstructured":"Bonomi P, Blumenthal G, Ferris AS et al (2018) Making lung cancer clinical trials more inclusive: recommendations for expanding eligibility criteria. J Thorac Oncol 13:748\u2013751. https:\/\/doi.org\/10.1016\/j.jtho.2018.02.013","journal-title":"J Thorac Oncol"},{"key":"4617_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"4617_CR6","unstructured":"CTCAE (2017) Common Terminology Criteria for Adverse Events (CTCAE). 155"},{"key":"4617_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2020.02.023","volume":"130","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Mazzaschi G, Barbieri F et al (2020) First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer 130:155\u2013167. https:\/\/doi.org\/10.1016\/j.ejca.2020.02.023","journal-title":"Eur J Cancer"},{"key":"4617_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","volume":"127","author":"E Felip","year":"2020","unstructured":"Felip E, Ardizzoni A, Ciuleanu T et al (2020) CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer 127:160\u2013172. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.019","journal-title":"Eur J Cancer"},{"key":"4617_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.027","author":"D Fg","year":"2020","unstructured":"Fg D, Maggio I, Massucci M et al (2020) ECOG performance status \u2265 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014a systematic review and meta-analysis of real world data. Lung Cancer. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.027","journal-title":"Lung Cancer"},{"key":"4617_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100355","author":"C Gridelli","year":"2022","unstructured":"Gridelli C, Peters S, Mok T et al (2022) First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100355","journal-title":"ESMO Open"},{"key":"4617_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.bjc.6603869","volume":"97","author":"N Helbekkmo","year":"2007","unstructured":"Helbekkmo N, Sundstr\u00f8m SH, Aaseb\u00f8 U et al (2007) Vinorelbine\/carboplatin vs gemcitabine\/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97:283\u2013289. https:\/\/doi.org\/10.1038\/sj.bjc.6603869","journal-title":"Br J Cancer"},{"key":"4617_CR12","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","volume":"27","author":"A Inoue","year":"2009","unstructured":"Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394\u20131400. https:\/\/doi.org\/10.1200\/JCO.2008.18.7658","journal-title":"J Clin Oncol"},{"key":"4617_CR13","doi-asserted-by":"publisher","first-page":"100550","DOI":"10.1016\/j.currproblcancer.2020.100550","volume":"44","author":"H Kancharla","year":"2020","unstructured":"Kancharla H, Gundu N, Pathak N et al (2020) Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: a retrospective analysis from routine clinical practice. Curr Probl Cancer 44:100550. https:\/\/doi.org\/10.1016\/j.currproblcancer.2020.100550","journal-title":"Curr Probl Cancer"},{"key":"4617_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1556-0864(15)30041-1","volume":"2","author":"PA Kosmidis","year":"2007","unstructured":"Kosmidis PA, Dimopoulos M-A, Syrigos K et al (2007) Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2:135\u2013140","journal-title":"J Thorac Oncol"},{"key":"4617_CR15","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998\u20132006. https:\/\/doi.org\/10.1001\/jama.2014.3741","journal-title":"JAMA"},{"key":"4617_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/ejh.13068","volume":"100","author":"KC Lakshmaiah","year":"2018","unstructured":"Lakshmaiah KC, Asati V, Babu KG et al (2018) Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B cell lymphoma. Eur J Haematol 100:644\u2013648. https:\/\/doi.org\/10.1111\/ejh.13068","journal-title":"Eur J Haematol"},{"key":"4617_CR17","unstructured":"LC-13 (2017) Questionnaires\u2014EORTC\u2014Quality of Life: EORTC\u2014Quality of Life. https:\/\/qol.eortc.org\/questionnaires\/, https:\/\/qol.eortc.org\/questionnaires\/. Accessed 29 Jul 2022"},{"key":"4617_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","volume":"12","author":"T Le Chevalier","year":"1994","unstructured":"Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360\u2013367. https:\/\/doi.org\/10.1200\/JCO.1994.12.2.360","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"4617_CR19","doi-asserted-by":"publisher","first-page":"S808","DOI":"10.1016\/annonc\/annonc1089","volume":"33","author":"SM Lee","year":"2022","unstructured":"Lee SM, Schulz C, Prabhash K, Han B, Szczesna A, Cortinovis DL, Rittmeyer A, Vicente-Baz D, Califano R, Tuan Anh L, Liu G, Cappuzzo F, Reyes Contreras JG, Reck M, Hu Y, Morris S, Hoeglander EK, Connors M, Vollan HKM, Peters S (2022) IPSOS: results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Ann Oncol 33(suppl 7):S808\u2013S869. https:\/\/doi.org\/10.1016\/annonc\/annonc1089","journal-title":"Ann Oncol"},{"key":"4617_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/JTO.0b013e318031d06f","volume":"2","author":"SS Leong","year":"2007","unstructured":"Leong SS, Toh CK, Lim WT et al (2007) A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and\/or are elderly. J Thorac Oncol 2:230\u2013236. https:\/\/doi.org\/10.1097\/JTO.0b013e318031d06f","journal-title":"J Thorac Oncol"},{"key":"4617_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","volume":"3","author":"RC Lilenbaum","year":"2008","unstructured":"Lilenbaum RC, Cashy J, Hensing TA et al (2008) Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3:125\u2013129. https:\/\/doi.org\/10.1097\/JTO.0b013e3181622c17","journal-title":"J Thorac Oncol"},{"key":"4617_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.12.027","author":"R Lobefaro","year":"2021","unstructured":"Lobefaro R, Viscardi G et al (2021) Immunotherapy in advanced non-small cell lung cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer (Amsterdam, Netherlands). https:\/\/doi.org\/10.1016\/j.lungcan.2020.12.027","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"4617_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30033-3","author":"G Middleton","year":"2020","unstructured":"Middleton G, Brock K, Savage J et al (2020) Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30033-3","journal-title":"Lancet Respir Med"},{"key":"4617_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lungcan.2013.04.008","volume":"81","author":"A Morabito","year":"2013","unstructured":"Morabito A, Gebbia V, Di Maio M et al (2013) Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 81:77\u201383. https:\/\/doi.org\/10.1016\/j.lungcan.2013.04.008","journal-title":"Lung Cancer"},{"key":"4617_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jpainsymman.2009.06.013","volume":"39","author":"J Myers","year":"2010","unstructured":"Myers J, Gardiner K, Harris K et al (2010) Evaluating correlation and interrater reliability for four performance scales in the palliative care setting. J Pain Symptom Manage 39:250\u2013258. https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.06.013","journal-title":"J Pain Symptom Manage"},{"key":"4617_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007309.pub2","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"2010","unstructured":"Non-Small Cell Lung Cancer Collaborative Group (2010) Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007309.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4617_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"4617_CR28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.annonc.2022.01.003","volume":"33","author":"A Patel","year":"2022","unstructured":"Patel A, Goldstein DA, Tannock IF (2022) Improving access to immunotherapy in low- and middle-income countries. Ann Oncol 33:360\u2013361. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.003","journal-title":"Ann Oncol"},{"key":"4617_CR29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/annonc\/mdf187","volume":"13","author":"E Radzikowska","year":"2002","unstructured":"Radzikowska E, G\u0142az P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 13:1087\u20131093. https:\/\/doi.org\/10.1093\/annonc\/mdf187","journal-title":"Ann Oncol"},{"key":"4617_CR30","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1097\/JTO.0000000000000334","volume":"9","author":"R Rami-Porta","year":"2014","unstructured":"Rami-Porta R, Bolejack V, Giroux DJ et al (2014) The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 9:1618\u20131624. https:\/\/doi.org\/10.1097\/JTO.0000000000000334","journal-title":"J Thorac Oncol"},{"key":"4617_CR31","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol 39:2339\u20132349. https:\/\/doi.org\/10.1200\/JCO.21.00174","journal-title":"J Clin Oncol"},{"key":"4617_CR32","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1200\/JCO.2009.21.9766","volume":"27","author":"C Reynolds","year":"2009","unstructured":"Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808\u20135815. https:\/\/doi.org\/10.1200\/JCO.2009.21.9766","journal-title":"J Clin Oncol"},{"key":"4617_CR33","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1183\/09031936.00034507","volume":"30","author":"JP Sculier","year":"2007","unstructured":"Sculier JP, Lafitte JJ, Paesmans M et al (2007) Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30:1186\u20131192. https:\/\/doi.org\/10.1183\/09031936.00034507","journal-title":"Eur Respir J"},{"key":"4617_CR34","doi-asserted-by":"publisher","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","volume":"4","author":"K Sehgal","year":"2021","unstructured":"Sehgal K, Gill RR, Widick P et al (2021) Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open 4:e2037120. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37120","journal-title":"JAMA Netw Open"},{"key":"4617_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310. https:\/\/doi.org\/10.1016\/0197-2456(89)90015-9","journal-title":"Control Clin Trials"},{"key":"4617_CR36","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3332\/ecancer.2022.1407","volume":"16","author":"A Singh","year":"2022","unstructured":"Singh A, Kapoor A, Noronha V et al (2022) ALK-positive advanced non-small cell lung cancer patients with poor performance status: outcomes in a real-world scenario. Ecancermedicalscience 16:1407. https:\/\/doi.org\/10.3332\/ecancer.2022.1407","journal-title":"Ecancermedicalscience"},{"key":"4617_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/bjc.1993.140","volume":"67","author":"JB S\u00f8rensen","year":"1993","unstructured":"S\u00f8rensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67:773\u2013775. https:\/\/doi.org\/10.1038\/bjc.1993.140","journal-title":"Br J Cancer"},{"key":"4617_CR38","doi-asserted-by":"publisher","unstructured":"Suidan AM, Roisman L, Belilovski Rozenblum A, et al (2019) Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. JGO 1\u20138. https:\/\/doi.org\/10.1200\/JGO.18.00216","DOI":"10.1200\/JGO.18.00216"},{"key":"4617_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. JCO 40:611\u2013625. https:\/\/doi.org\/10.1200\/JCO.21.01626","journal-title":"JCO"},{"key":"4617_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.lungcan.2022.01.024","volume":"166","author":"M Tang","year":"2022","unstructured":"Tang M, Lee CK, Lewis CR et al (2022) Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. Lung Cancer 166:40\u201348. https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.024","journal-title":"Lung Cancer"},{"key":"4617_CR41","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00432-018-2695-4","volume":"144","author":"A Tryakin","year":"2018","unstructured":"Tryakin A, Fedyanin M, Bulanov A et al (2018) Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and\/or poor performance status. J Cancer Res Clin Oncol 144:1817\u20131823. https:\/\/doi.org\/10.1007\/s00432-018-2695-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"4617_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12890-017-0452-0","volume":"17","author":"L Zhao","year":"2017","unstructured":"Zhao L, Leung L-H, Wang J et al (2017) Association between Charlson comorbidity index score and outcome in patients with stage IIIB\u2013IV non-small cell lung cancer. BMC Pulm Med 17:112. https:\/\/doi.org\/10.1186\/s12890-017-0452-0","journal-title":"BMC Pulm Med"},{"key":"4617_CR43","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","volume":"31","author":"M Zukin","year":"2013","unstructured":"Zukin M, Barrios CH, Pereira JR et al (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31:2849\u20132853. https:\/\/doi.org\/10.1200\/JCO.2012.48.1911","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04617-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04617-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04617-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T08:23:21Z","timestamp":1689755001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04617-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4617"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04617-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2225501\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose<i>.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with Good Clinical Practice and approved by the institute ethics committee (IECPG-63428.11.2019 dated 29.11.2019).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All information has been anonymised and no identifying images or figures are included in the paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}